Evidence map›Paper›PMID 30515766›Full record

SynthesisActa anaesthesiologica Scandinavica2019

Dopamine in critically ill patients with cardiac dysfunction: A systematic review with meta-analysis and trial sequential analysis.

Bart Hiemstra, Geert Koster, Jørn Wetterslev, Christian Gluud, Janus C Jakobsen, Thomas W L Scheeren, Frederik Keus, Iwan C C van der Horst

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Acta anaesthesiologica Scandinavica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Role of Dopamine in the Heart in Health and Disease.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Current use of vasopressors in septic shock.Annals of intensive care · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Bart HiemstraDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0001-6547-2138
Geert KosterDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jørn WetterslevThe Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research, Copenhagen, Denmark.
Christian GluudThe Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research, Copenhagen, Denmark.
Janus C JakobsenThe Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research, Copenhagen, Denmark.
Thomas W L ScheerenDepartment of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Frederik KeusDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Iwan C C van der HorstDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0003-3891-8522
University Medical Center Groningen · NLHolbæk Sygehus · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDopamine has been used in patients with cardiac dysfunction for more than five decades. Yet, no systematic review has assessed the effects of dopamine in critically ill patients with cardiac dysfunction.

methodsThis systematic review was conducted following The Cochrane Handbook for Systematic Reviews of Interventions. We searched for trials including patients with observed cardiac dysfunction published until 19 April 2018. Risk of bias was evaluated and Trial Sequential Analyses were conducted. The primary outcome was all-cause mortality at longest follow-up. Secondary outcomes were serious adverse events, myocardial infarction, arrhythmias, and renal replacement therapy. We used GRADE to assess the certainty of the evidence.

resultsWe identified 17 trials randomising 1218 participants. All trials were at high risk of bias and only one trial used placebo. Dopamine compared with any control treatment was not significantly associated with relative risk of mortality (60/457 [13%] vs 90/581 [15%]; RR 0.91; 95% confidence interval 0.68-1.21) or any other patient-centred outcomes. Trial Sequential Analyses of all outcomes showed that there was insufficient information to confirm or reject our anticipated intervention effects. There were also no statistically significant associations for any of the outcomes in subgroup analyses by type of comparator (inactive compared to potentially active), dopamine dose (low compared to moderate dose), or setting (cardiac surgery compared to heart failure).

conclusionEvidence for dopamine in critically ill patients with cardiac dysfunction is sparse, of low quality, and inconclusive. The use of dopamine for cardiac dysfunction can neither be recommended nor refuted.

Indexed as

Cardiotonic AgentsClinical Trials as TopicCritical IllnessDopamineHeart DiseasesHumansCardiotonic AgentsDopamine

Identifiers

PMID30515766
PMCPMC6587868
OpenAlexW2903491519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.